According to RedSeer Report, API Holdings Limited is India’s biggest online healthcare platform (depending on GMV of items and solutions provided for the year ended March 31, 2021). Pharmeasy IPO (API Holdings IPO) will hit the market in February 2021.
Table of Contents
About API Holdings
They run an integrated, end-to-end business with the goal of meeting users’ healthcare requirements at all phases of the process: supplying electronic tools and details on disease and wellbeing, offering teleconsultation, giving diagnostics and radiology tests, and distributing treatment protocols, such as products and devices.
The skills that set us apart are their custom-built proprietary system, unified data portals, supply chain skills, and deep awareness of the dynamic interplay between the numerous sub-segments of India’s healthcare sector.
Their platforms are available throughout India’s major cities and rural areas.
Footprints
Their technology tools and capabilities help clients address problems while also allowing them to take advantage of a linked network.
At the same time, they help them to establish a larger presence, allowing their platform to reach a larger number of stakeholders across the country.
their operations are spread around the country, with last-mile delivery capabilities in over 18,587 pin codes (as of June 2021) via the PharmEasy marketplace, enabling them to provide service to the ordinary man at an affordable price.
Their platforms have grown to serve people from all walks of life and across India’s urban, semi-urban, and rural areas.
History
Dialhealth.com was founded by several of their Founders (Siddharth, Hardik, and Harsh) in 2012. It was an online order platform that provided tele-consultation, diagnostic lab pick-ups, and medical supply delivery services.
Despite the fact that these Founders had several offers, they only observed significant demand for product delivery, and as a result, offerings other than product delivery were subsequently pared back.
As Ascent grew, its procurement and supply chain capabilities improved, prompting their Founders to apply what they’d learned to create the technology that supports the PharmEasy marketplace.
PharmEasy is a healthcare smart app that allows users to get pharmaceutical medications on-demand and have them delivered to their homes.
Pharmeasy IPO
API Holdings Limited, headquartered in Mumbai has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 6,250 crores on 08 November 2021.
The offer includes fresh issue of INR 6200 crores value equity shares and there is no offer for sale (OFS) by the promoters mentioned in the DRHP. They are looking for a pre-IPO placement of 1,250 crores in this issue.
They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year/period ended ( in Cr.) | ||||
|---|---|---|---|---|---|
| 30-Jun-21 | 31-Mar-21 | 31-Mar-20 | |||
| Total Assets | 5,843.56 | 4,905.34 | 572.47 | ||
| Total Revenue | 1,207.26 | 2,360.66 | 737.45 | ||
| Loss After Tax | (305.96) | (644.83) | (335.07) | ||
Basic and Diluted Earnings Per Share
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2021 | (1.88) | (1.88) | 2 |
| Financial Year 2020 | (1.17) | (1.17) | 1 |
| Weighted Average | (1.64) | (1.64) | |
| 30 June 2021 | (0.70) | (0.70) |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of the offer
The following business strengths, they feel, enable them to stay competitive in the market:
- Stakeholder interactions throughout the healthcare value chain are part of an integrated business strategy.
- PharmEasy is a well-known brand.
- An method that is based on technology.
- Acquiring and integrating businesses is something I’ve done before.
- Capabilities of a scalable supply chain.
- Scalable and resilient business model with increasing financial metrics.
- A founding and professional management team that is seasoned, motivated, and ambitious.
Pharmeasy IPO Peer Comparison
There are no publicly traded organizations in India with a portfolio of products and services equivalent to theirs, or a scale of operations equivalent to theirs.
Pharmeasy IPO Details
| IPO Opening Date | February 2021 |
| IPO Closing Date | February 2021 |
| Issue Type | Book Building |
| Face Value | 1 per share |
| IPO Price | 0 to 0 per equity share |
| Market Lot | – |
| Min Order Quantity | – |
| Listing At | BSE, NSE |
| Issue Size | 6250 crores |
| Fresh Issue | 6250 Crores |
| Offer for Sale | – |
Pharmeasy IPO Date
Pharmeasy IPO opening date is February 2021, and the closing date is February 2021. The Pharmeasy issue may list in February 2021.
| IPO Opening Date | February 2021 |
| IPO Closing Date | February 2021 |
| Basis of Allotment Date | February 2021 |
| Initiation of Refunds | February 2021 |
| Credit of Shares to Demat Account | February 2021 |
| IPO Listing Date | February 2021 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 75 |
Roughly
equivalent
|
| Non Institutional Investor | 15 |
Roughly
equivalent
|
| Retail | 10 | Minimum level of 1 lot, based on availability, for every shareholder. |
Pharmeasy IPO Allotment Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of Pharmeasy IPO.
Pharmeasy IPO GMP
Pharmeasy IPO Grey Market Premium is 0. You can check out GMP of Other IPOs on below Links:
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 | |||
| February 2021 |
Check Out the GMP of all Other IPOs
Pharmeasy IPO Review
Pharmeasy IPO review will depend on the price band which will be announced after SEBI approval. Whenever it will be announced we will update you regarding review of Pharmeasy IPO is good or bad.
Pharmeasy IPO Risk
- Their success is contingent on the digital healthcare industry’s continuous expansion and customer acceptance of digital healthcare services.
- Any failure by Axelia to effectively handle the PharmEasy marketplace might have a major and negative impact on their business, which in turn could have a negative impact on theirs.
- It is vital to their business that they maintain their brand image and reputation among participants on their platform as well as the media.
- They have only recently completed large acquisitions and have a limited operating history, including in the digital healthcare market.
- New rules and regulations relevant to ecommerce may be implemented by the Indian government, resulting in new compliance obligations.
Other Threats
- They have previously experienced losses and negative cash flows, and they may continue to experience losses and negative cash flows in the future.
- They may face medical responsibility claims, which might result in significant reputational harm and financial costs.
- In relation of their financial statements, their Statutory Auditors have provided emphasis of matter paragraphs.
- A pandemic of COVID-19, or a related public health threat, might have a negative impact on their business.
- They may not be able to detect or eliminate scam or other wrongdoing on their platform by their employees or third parties.
- Their vendors provide them pharmaceutical and healthcare items. Their collaboration is vulnerable to a number of threats.
Supply Chain
Their primary belief is that technology must play a critical role in seamlessly connecting all of the different healthcare segments, resulting in better health outcomes for clients and other potential advantages for all stakeholders.
They ‘ve worked hard to create a connected digital environment for every level of the supply chain, and the patient experience.
In the pharmaceutical industry, for example, their technology services assist us empower inexpensive healthcare and overcome end-to-end supply chain issues via increased clarity, genuine medicines, narrower delivery timelines, enhanced fill rates, easy returns, and online payment, resulting in supply chain accountability.
Business Approach
They collaborate with customers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors, and diagnostic and radiological labs to provide technology-enabled services.
They’ve been able to create ties with numerous stakeholders in the healthcare value chain thanks to their expanding nationwide presence, integrated ecosystem approach, and multiple synergistic solutions.
They are one of the nation ‘s leading digital first platforms, aggregating healthcare data and connecting traditionally dispersed players.
Not only do they want to establish a solid technological platform, but they also want to integrate actionable insights and intelligence into every part of the healthcare value chain.
Pharmeasy
In terms of GMV of items and services supplied on the platform, PharmEasy is India’s top healthcare super app for users (offering online pharmacy, OTC, teleconsultation, and diagnostics services). They own the “PharmEasy” brand, and the PharmEasy marketplace is powered by their own technological platform.
They’ve licenced the brand and technology to Axelia, a subsidiary of Aarman in which they possess a 19.99 percent stake. The PharmEasy marketplace is run by Axelia.
They created their platform and technologies in such a way that they can address a variety of use cases throughout a consumer’s healthcare journey. They intend to keep introducing new features to expand these potential in the future.
Strategies
Connecting different components of the healthcare ecosystem, they believe, is critical to generating value for all stakeholders.
To that aim, they’ve invested in processes, technologies, and people, and they ‘ll continue to do so as they build a more connected and integrated ecosystem.
While they now provide a wide range of services, they believe that by using their data and technology stack, they can achieve even deeper integration across their own offerings as well as with the rest of the healthcare business.
they’ll put this plan into action by establishing new use cases and user-friendly tech layers (for both clients and stakeholders) on top of physical and manual levels, as well as allowing platform-wide access to aggregate data and insights.
Pharmeasy IPO Brokerage views
- Yes Securities : Not Updated
- Choice Brokering: Not Updated
- Axis Securities: Not Updated
- IIFL Securities: Not Updated
- Trade swift: Not Updated
- Anand Rathi : Not Updated
- ICICI Securities: Not Updated
Pharmeasy IPO Subscription Status
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| February 2021 | 1 | |||||
| February 2021 | 2 | |||||
| February 2021 | 3 |
Principal Shareholders
- Prosus
- Temasek
- TPG
Principal Shareholders’s Holding
| Pre Issue Share Holding | 0% |
| Post Issue Share Holding |
Pharmeasy IPO Prospectus
Contact Details
API Holdings Limited
902, 9th Floor, Raheja Plaza 1,
B-Wing,Opposite R-City Mall,
L.B.S. Marg, Ghatkopar West,
Mumbai 400 086, Maharashtra, India
Tel: +91 22 6255 6255
E-mail: [email protected]
Website: www.apiholdings.in
Registrar
Link Intime India Private Limited
C 101, 247 Park, L.B.S. Marg, Vikhroli (West),
Mumbai 400 083
Maharashtra, India
Tel: +91 22 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in
Lead Manager(s)
- Kotak Mahindra Capital Company Limited
- Morgan Stanley India Company Private Limited
- BofA Securities India Limited
- Citigroup Global Markets India Private Limited
- JM Financial Limited
We hope we are able to answer all your questions about Pharmeasy IPO. If you don’t have a Demat account, open it now with Zerodha best trading app of India.
Disclaimer
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
We do not engage in grey market trading or facilitate the purchase or sale of IPO forms. We don’t endorse such activities at all. We are sticky against such activities & never advise anyone to trade in grey market at all.
FAQ
Pharmeasy IPO Opening Date?
Pharmeasy IPO will open in February 2021.
Pharmeasy IPO Listing Date?
Pharmeasy IPO will list in February 2021.
Pharmeasy IPO GMP Today?
Pharmeasy IPO Grey Market Premium is INR 0 .
Pharmeasy IPO Allotment Date?
Pharmeasy IPO basis of allotment will be in February 2021.
Lot size for Pharmeasy IPO?
Lot size for Pharmeasy IPO is 0.
